Product Information
DABIGATRAN ETEXILATE 150 MG CP is a generic product labeled by Major Pharmaceuticals, priced at $0.8226 per EA under NDC 00904725510. Its NADAC has been published 51 times since Sep 3, 2025.
FDA first approved this application on Mar 11, 2020. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The Low Outlier badge above means this manufacturer's average price in the Dabigatran Etexilate market falls below Q1 − 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
150 mg/1
Manufacturer
Major PharmaceuticalsNDC
00904725510
Classification
Generic
Dosage Form
CAPSULE, COATED PELLETS
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
DABIGATRAN ETEXILATE MESYLATEApproval Type
Generic (ANDA)
FDA Application
ANDA208040FDA Approved
3/11/2020
TE Code
AB
On Market Since
6/23/2025
Pharmacological Classes
Price Statistics
The NADAC for DABIGATRAN ETEXILATE 150 MG CP has been published 51 times since Sep 3, 2025, and over the history we have for it it has declined 34.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.8226 per EA |
|---|---|
| All-time high | $1.2631 (Sep 10, 2025) |
| All-time low | $0.8226 (Aug 19, 2026) |
| 52-week high | $1.2631 |
| 52-week low | $0.8226 |
| Median price | $0.8830 |
| Average price | $0.9513 |
| Largest weekly change | -9.3% (Sep 17, 2025) |
| Weeks tracked | 51 |
| Tracking since | Sep 3, 2025 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of DABIGATRAN ETEXILATE 150 MG CP?
The current National Average Drug Acquisition Cost (NADAC) for DABIGATRAN ETEXILATE 150 MG CP, manufactured by Major Pharmaceuticals, is $0.8226 per EA (NDC 00904725510), effective Aug 19, 2026.
How has the price of DABIGATRAN ETEXILATE 150 MG CP changed over time?
Over the history we have for it, the NADAC for DABIGATRAN ETEXILATE 150 MG CP has declined 34.9%. It has been tracked across 51 weekly CMS publications since Sep 3, 2025.
What are the highest and lowest recorded NADAC prices for DABIGATRAN ETEXILATE 150 MG CP?
Since Sep 3, 2025, the NADAC for DABIGATRAN ETEXILATE 150 MG CP has ranged from a low of $0.8226 (Aug 19, 2026) to a high of $1.2631 (Sep 10, 2025), with a median of $0.8830 per EA.
Are there cheaper alternatives to DABIGATRAN ETEXILATE 150 MG CP?
5 manufacturers publish a NADAC-priced product with the same active ingredient and strength as DABIGATRAN ETEXILATE 150 MG CP in a comparable dosage form, but none are currently priced below it.
Who manufactures DABIGATRAN ETEXILATE 150 MG CP?
DABIGATRAN ETEXILATE 150 MG CP (NDC 00904725510) is labeled by Major Pharmaceuticals, and CMS classifies it as a generic product.